Sab Biotherapeutics, Inc. · NASDAQ:SABS
BVF PARTNERS L P/IL reported a 9.99% stake in Sab Biotherapeutics, Inc. (Schedule 13G/A)
Event Sep 30, 2025 · Filed Nov 14, 2025
BVF PARTNERS L P/IL reported a 9.99% stake in Sab Biotherapeutics, Inc., 5,167,618 shares, as a passive investor on Sep 30, 2025. Filed Nov 14, 2025 (Schedule 13G/A).
- Stake
- 9.99%
- Shares
- 5,167,618
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 10 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 6.10% | 3,041,111 |
| BVF I GP LLC | 6.10% | 3,041,111 |
| BIOTECHNOLOGY VALUE FUND II LP | 4.20% | 2,075,714 |
| BVF II GP LLC | 4.20% | 2,075,714 |
| Biotechnology Value Trading Fund OS LP | 0.09% | 44,444 |
| BVF Partners OS Ltd. | 0.09% | 44,444 |
| BVF GP HOLDINGS LLC | 9.90% | 5,116,825 |
| BVF PARTNERS L P/IL | 9.99% | 5,167,618 |
| BVF INC/IL | 9.99% | 5,167,618 |
| LAMPERT MARK N | 9.99% | 5,167,618 |
Source
Related
- Sab Biotherapeutics, Inc.
- Bvf Partners L P
- Sab Biotherapeutics, Inc. shareholders
- Schedule 13G/A · Bvf Partners L P · Feb 17, 2026
- Form 4 · Kropotova Alexandra · Sep 18, 2026
- Schedule 13G/A · Vivo Opportunity, LLC · Aug 14, 2026
- Schedule 13G/A · Woodline Partners LP · Aug 14, 2026
- Schedule 13G/A · Balyasny Asset Management L.P. · Aug 14, 2026
- Schedule 13G/A · Caligan Partners LP · Aug 14, 2026